2772-6118

EJC Skin Cancer

Elsevier

View prefix report (10.1016)

Health Score

0 Poor

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1140 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1140 DOIs
2

Attach ORCID iDs across 1072 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact1072 DOIs
3

Deposit reference lists for 1026 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact1026 DOIs

DOIs for this ISSN

Showing the top 5 of 1140 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Preoperative evaluation of high-risk basal cell carcinoma wi… (10.1016/j.ejcskn.2023.100015)
Abstract ORCID
65.05 19
2 Adjuvant systemic therapy in melanoma: Relative versus absol… (10.1016/j.ejcskn.2024.100021)
Abstract ORCID
53.96 11
3 Right-Sided Lateralisation of Basal Cell Carcinoma and Squam… (10.1016/j.ejcskn.2024.100052)
Abstract References ORCID
45.15 3
4 Phase 1 dose escalation trial of FLASH radiotherapy in patie… (10.1016/j.ejcskn.2025.100507)
Abstract References ORCID
45.15 3
5 Real-world data on tolerability and clinical response of cem… (10.1016/j.ejcskn.2023.100007)
Abstract ORCID
38.91 5
6 A systematic review of economic evaluations for the interven… (10.1016/j.ejcskn.2023.100008)
Abstract ORCID
38.91 5
7 Quality of life issues faced by patients with keratinocyte c… (10.1016/j.ejcskn.2024.100022)
Abstract ORCID
38.91 5
8 Multimodal skin imaging of a dermatofibrosarcoma protuberans… (10.1016/j.ejcskn.2024.100061)
Abstract References ORCID
35.78 2
9 Novel, non-invasive method for classification of melanocytic… (10.1016/j.ejcskn.2024.100099)
Abstract References ORCID
35.78 2
10 The health economic impact of the 31-gene expression profile… (10.1016/j.ejcskn.2024.100109)
Abstract References ORCID
35.78 2
11 RNA helicase DHX9 enables PBX1 mRNA translation by unfolding… (10.1016/j.ejcskn.2024.100135)
Abstract References ORCID
35.78 2
12 Pembrolizumab treatment for advanced pleomorphic dermal sarc… (10.1016/j.ejcskn.2024.100205)
Abstract References ORCID
35.78 2
13 Neutrophil-lymphocyte ratio as a predictive marker for progr… (10.1016/j.ejcskn.2024.100236)
Abstract References ORCID
35.78 2
14 DETECTION-2 feasibility: A Phase 2 trial comparing adjuvant… (10.1016/j.ejcskn.2025.100585)
Abstract References ORCID
35.78 2
15 A Phase 3 trial of fianlimab + cemiplimab versus pembrolizum… (10.1016/j.ejcskn.2025.100587)
Abstract References ORCID
35.78 2
16 Prospective multicenter evaluation of a clinicopathologic an… (10.1016/j.ejcskn.2025.100589)
Abstract References ORCID
35.78 2
17 Efficacy and safety of lifileucel, an autologous tumor-infil… (10.1016/j.ejcskn.2025.100624)
Abstract References ORCID
35.78 2
18 Sonidegib reduced tumor burden in patients with advanced bas… (10.1016/j.ejcskn.2024.100267)
Abstract ORCID
34.95 4
19 Independent association of sex, age and the melanoma subtype… (10.1016/j.ejcskn.2024.100020)
Abstract ORCID
30.10 3
20 Electronic patient-reported outcomes, fever management, and… (10.1016/j.ejcskn.2024.100254)
Abstract ORCID
30.10 3
21 Sex-specific and sex hormonal-related differences in melanom… (10.1016/j.ejcskn.2024.100266)
Abstract ORCID
30.10 3
22 Neoadjuvant ipilimumab plus nivolumab in locally advanced me… (10.1016/j.ejcskn.2023.100003)
Abstract
26.03 10
23 Management of patients with skin adnexal carcinomas (10.1016/j.ejcskn.2023.100006)
Abstract
25.00 9
24 German S3 guideline “actinic keratosis and cutaneous squamou… (10.1016/j.ejcskn.2023.100004)
Abstract
23.86 8
25 Histologic and genomic characterization of a primary mucinou… (10.1016/j.ejcskn.2023.100011)
Abstract ORCID
23.86 2
26 Statin use in resected, high-risk cutaneous melanoma: A mult… (10.1016/j.ejcskn.2024.100017)
Abstract ORCID
23.86 2
27 Morphometric differences between basal cell carcinomas &… (10.1016/j.ejcskn.2024.100024)
Abstract ORCID
23.86 2
28 LASSO logistic regression reveals a mixed MiRNA and serum-ma… (10.1016/j.ejcskn.2024.100260)
Abstract ORCID
23.86 2
29 Morpho-phenotypic characterization of melanoma brain metasta… (10.1016/j.ejcskn.2024.100263)
Abstract ORCID
23.86 2
30 Real-World efficiency of pembrolizumab in metastatic melanom… (10.1016/j.ejcskn.2024.100271)
Abstract ORCID
23.86 2
31 Long lasting complete regression of a metastatic polyomaviru… (10.1016/j.ejcskn.2024.100275)
Abstract ORCID
23.86 2
32 Prognostic significance of sentinel node tumor burden in Mer… (10.1016/j.ejcskn.2025.100728)
Abstract ORCID
23.86 2
33 European Journal of Skin Cancer Editorial (10.1016/j.ejcskn.2023.100001)
Abstract References ORCID
22.58 1
34 Comparison of the efficacy of skin examination using 3D tota… (10.1016/j.ejcskn.2024.100038)
Abstract References ORCID
22.58 1
35 Interim analysis of the multinational, post-authorisation sa… (10.1016/j.ejcskn.2024.100044)
Abstract References ORCID
22.58 1
36 What is the quality-of-life impact of basal cell carcinoma i… (10.1016/j.ejcskn.2024.100055)
Abstract References ORCID
22.58 1
37 Stratified processing of skin lesions through deep learning (10.1016/j.ejcskn.2024.100063)
Abstract References ORCID
22.58 1
38 Epidemiological indicators of melanoma in the Republic of Uz… (10.1016/j.ejcskn.2024.100086)
Abstract References ORCID
22.58 1
39 Estimating Occupational Exposure to Ultraviolet Radiation Us… (10.1016/j.ejcskn.2024.100087)
Abstract References ORCID
22.58 1
40 Staging of Mucosal Melanoma of the Head and Neck (10.1016/j.ejcskn.2024.100108)
Abstract References ORCID
22.58 1
41 Unlocking Potential in Clinical Practice: A Comprehensive As… (10.1016/j.ejcskn.2024.100111)
Abstract References ORCID
22.58 1
42 Using a clinicopathologic and gene expression model to predi… (10.1016/j.ejcskn.2024.100114)
Abstract References ORCID
22.58 1
43 “One spot check”; a new strategy to increase dermatology acc… (10.1016/j.ejcskn.2024.100116)
Abstract References ORCID
22.58 1
44 Discoidin domain receptor 1, a melanoma immunomodulator (10.1016/j.ejcskn.2024.100121)
Abstract References ORCID
22.58 1
45 Dupilumab for the treatment of bullous pemphigoid triggered… (10.1016/j.ejcskn.2024.100150)
Abstract References ORCID
22.58 1
46 First-line Nivolumab plus Ipilimumab in patients with advanc… (10.1016/j.ejcskn.2024.100153)
Abstract References ORCID
22.58 1
47 Updated outcomes of AdjuMel study: real-world data in patien… (10.1016/j.ejcskn.2024.100169)
Abstract References ORCID
22.58 1
48 Does the interval between melanoma diagnosis and surgery hav… (10.1016/j.ejcskn.2024.100172)
Abstract References ORCID
22.58 1
49 Skin adnexal carcinomas DNA genomic profiling uncovers oncog… (10.1016/j.ejcskn.2024.100206)
Abstract References ORCID
22.58 1
50 Squamoid Eccrine Ductal Carcinoma: A Case Series of Three Pa… (10.1016/j.ejcskn.2024.100208)
Abstract References ORCID
22.58 1